AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12151429 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH 150 IU and LH activity 75 IU
Number of subjects: 120
Study 12151429 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH 150 IU and LH activity 150 IU
Number of subjects: 120
Study 9475135 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific exercise intervention
Number of subjects: 42
Study 9475135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 7618621 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform
Number of subjects: 25
Study 7618621 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study 2793755 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ppm of ozone (O3) exposure for 2 hours
Number of subjects: 14
Study 346427 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole coffee
Number of subjects: 0
Study 346427 — intervention group
Group type: COMPARATOR
Intervention: De-caffeinated coffee
Number of subjects: 0
Study 28589947 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG+RES (epigallocatechin‐3‐gallate and resveratrol, 282 and 80 mg/day, respectively)
Number of subjects: 37
Study 28589947 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 37
Study 25880968 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Oropharyngeal Decontamination (SOD)
Number of subjects: 5
Study 25880968 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Digestive Decontamination (SDD)
Number of subjects: 5
Study 23325162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC)
Number of subjects: 173
Study 23325162 — intervention group
Group type: COMPARATOR
Intervention: Dextrose (placebo)
Number of subjects: 173
Study 21103659 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg and placebo (n=68)
Number of subjects: 207
Study 21103659 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg and aspirin 100 mg (n=63)
Number of subjects: 207
Study 21103659 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg (n=76)
Number of subjects: 207
Study 19033877 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (cutaneous anesthesia) applied to the lower leg
Number of subjects: 40
Study 19033877 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 17939194 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetotropic therapy (Propranolol, Metoclopramid, Atropine)
Number of subjects: 67
Study 17939194 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxic adaptation
Number of subjects: 67
Study 16083511 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian electrocauterization
Number of subjects: 36
Study 16083511 — intervention group
Group type: COMPARATOR
Intervention: Control group (ovulatory women with unexplained infertility)
Number of subjects: 36
Study 12154154 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy
Number of subjects: 29
Study 12154154 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Severity
Number of subjects: 29
Study 12154154 — intervention group
Group type: COMPARATOR
Intervention: Dementia Severity, Executive Dysfunction, Disinhibition
Number of subjects: 29
Study 11490531 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 294
Study 11490531 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipobroman
Number of subjects: 294
Study 11490531 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 294
Study 7516263 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter oily chemoembolization
Number of subjects: 127
Study 7516263 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 127
Study 2688937 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories (2800 mg for 3 days)
Number of subjects: 56
Study 2688937 — intervention group
Group type: COMPARATOR
Intervention: Piperaquine phosphate (control)
Number of subjects: 56
Study 2688937 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin suppositories
Number of subjects: 56
Study 7014 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexotan (bromazepam)
Number of subjects: 0
Study 7014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30761667 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' electronic PRO-CTCAE reporting with real-time feedback to clinicians
Number of subjects: 0
Study 30761667 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28792587 — intervention group
Group type: EXPERIMENTAL
Intervention: EMGB
Number of subjects: 42
Study 28792587 — intervention group
Group type: COMPARATOR
Intervention: Cyclic NMES
Number of subjects: 42
Study 25460033 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes (e‐cigs)
Number of subjects: 23
Study 25460033 — intervention group
Group type: COMPARATOR
Intervention: Marlboro® cigarettes
Number of subjects: 23
Study 24320832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Illness Management and Recovery (IMR) program
Number of subjects: 97
Study 24320832 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 97
Study 21600005 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplement (MMS) at two times the recommended dietary allowance (RDA)
Number of subjects: 214
Study 21600005 — intervention group
Group type: COMPARATOR
Intervention: Standard of care supplement of 6 multivitamins (MV)
Number of subjects: 214
Study 19489239 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually designed trans‐fissure approach
Number of subjects: 90
Study 16685052 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 18
Study 16685052 — intervention group
Group type: COMPARATOR
Intervention: Orange juice
Number of subjects: 18
Study 16685052 — intervention group
Group type: COMPARATOR
Intervention: Furanocoumarin-free grapefruit juice
Number of subjects: 18
Study 15273083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 58
Study 15273083 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 58
Study 11763409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 80
Study 11763409 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 80
Study 11763409 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HRT and Alendronate
Number of subjects: 80
Study 11763409 — intervention group
Group type: COMPARATOR
Intervention: Healthy perimenopausal controls
Number of subjects: 80
Study 9249883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administration of furosemide (twice daily)
Number of subjects: 8
Study 9249883 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of furosemide (over 24 hours)
Number of subjects: 8
Study 9249883 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administration of furosemide
Number of subjects: 8
Study 9249883 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of furosemide
Number of subjects: 8
Study 8491934 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial treatment (amoxicillin, amoxicillin clavulanate potassium, or trimethoprim‐sulfamethoxazole)
Number of subjects: 96
Study 8491934 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial medication
Number of subjects: 96
Study 8491934 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 96
Study 8491934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 96
Study 3306809 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat treatment combined with radiation
Number of subjects: 10
Study 3306809 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 10
Study 31280363 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative body‐mind‐spirit intervention (I‐BMS)
Number of subjects: 157
Study 31280363 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 157
Study 30150651 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based stationary cycling during pregnancy (20-36 weeks of gestation)
Number of subjects: 84
Study 30150651 — intervention group
Group type: COMPARATOR
Intervention: Usual activity (control group)
Number of subjects: 84
Study 27255874 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 236
Study 27255874 — intervention group
Group type: EXPERIMENTAL
Intervention: S.A.L.T. device
Number of subjects: 236
Study 27255874 — intervention group
Group type: COMPARATOR
Intervention: Standard laryngoscope
Number of subjects: 236
Study 24825135 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 3% ointment
Number of subjects: 46
Study 24825135 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 46
Study 23586728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg once daily for 56 days
Number of subjects: 321
Study 23586728 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 56 days
Number of subjects: 321
Study 23586728 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 100 mg
Number of subjects: 321
Study 23586728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 20680689 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical levels of depression
Number of subjects: 0
Study 20680689 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of depressed affect and clinical asthma features
Number of subjects: 0
Study 20680689 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of illness burden
Number of subjects: 0
Study 20680689 — intervention group
Group type: EXPERIMENTAL
Intervention: Family features and a child missing school
Number of subjects: 0
Study 17889580 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine 600 mg daily for 10 days
Number of subjects: 20
Study 17889580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17277852 — intervention group
Group type: EXPERIMENTAL
Intervention: Early steroid withdrawal with tacrolimus (FK) and mycophenolate mofetil (MMF)
Number of subjects: 56
Study 17277852 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppressive therapy with steroids, cyclosporine and azathioprine or steroids, FK and MMF (Control Group B)
Number of subjects: 56
Study 12830070 — intervention group
Group type: EXPERIMENTAL
Intervention: parecoxib/valdecoxib
Number of subjects: 462
Study 12830070 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 462
Study 11108786 — intervention group
Group type: EXPERIMENTAL
Intervention: TPGDA
Number of subjects: 10
Study 11108786 — intervention group
Group type: EXPERIMENTAL
Intervention: UV‐resin
Number of subjects: 10
Study 9001824 — intervention group
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom (one capsule daily, 10 days per month, for 3 consecutive months)
Number of subjects: 587
Study 1355099 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoic acid (0.1% cream) applied topically for 4 days
Number of subjects: 12
Study 1355099 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment applied topically for 4 days
Number of subjects: 12
Study 1355099 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoic acid (1 microM) applied to cultured normal human keratinocytes for 4 days
Number of subjects: 12
Study 3883728 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 10
Study 3883728 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 10
Study 29907153 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP)
Number of subjects: 61
Study 29907153 — intervention group
Group type: COMPARATOR
Intervention: Higher-carbohydrate diet (HC)
Number of subjects: 61
Study 26979631 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms related to protein kinase C-α (PRKCA)
Number of subjects: 833
Study 26979631 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphism related to fms-related tyrosine kinase 1 (FLT1)
Number of subjects: 833
Study 26979631 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms related to matrix metalloproteinase-2 (MMP2), tissue inhibitor of matrix metalloproteinase-2 (TIMP2), and interleukin 16 (IL16)
Number of subjects: 833
Study 26979631 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms related to MMP2, matrix metalloproteinase-1 (MMP1), and leukemia inhibitory factor receptor antisense RNA 1 (LIFR-AS1)
Number of subjects: 833
Study 26979631 — intervention group
Group type: COMPARATOR
Intervention: Ancestry estimates
Number of subjects: 833
Study 24903620 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health behaviour intervention
Number of subjects: 1445
Study 24903620 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only control
Number of subjects: 1445
Study 22339485 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc‐4x
Number of subjects: 38
Study 22339485 — intervention group
Group type: EXPERIMENTAL
Intervention: 4xCP
Number of subjects: 38
Study 20191574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic and psychosocial treatment
Number of subjects: 100
Study 20191574 — intervention group
Group type: EXPERIMENTAL
Intervention: New medications
Number of subjects: 100
Study 18419234 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial emotion recognition task
Number of subjects: 25
Study 18419234 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambiguous emotional stimuli
Number of subjects: 25
Study 18419234 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal training
Number of subjects: 25
Study 18419234 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 25
Study 16084150 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezosentan (5 mg/h for 30 minutes, then 1 mg/h for 24-72 hours)
Number of subjects: 1760
Study 16084150 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1760
Study 12612363 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (adequate treatment with at least three of five core modules)
Number of subjects: 671
Study 12612363 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (adequate treatment)
Number of subjects: 671
Study 12612363 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (all parents randomised to treatment)
Number of subjects: 671
Study 12612363 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoke-free Kids programme (treated children)
Number of subjects: 671
Study 12612363 — intervention group
Group type: COMPARATOR
Intervention: Control group (344 participants)
Number of subjects: 671
Study 10565454 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta patients with OI III/IV and/or qualitative collagen defect
Number of subjects: 63
Study 10565454 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteogenesis imperfecta patients with OI I and/or quantitative collagen defect
Number of subjects: 63
Study 10565454 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall OI patients
Number of subjects: 63
Study 8743361 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D video system
Number of subjects: 30
Study 8743361 — intervention group
Group type: COMPARATOR
Intervention: 2-D video system
Number of subjects: 30
Study 1836422 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-sufentanil
Number of subjects: 47
Study 1836422 — intervention group
Group type: COMPARATOR
Intervention: Enflurane-sufentanil
Number of subjects: 47
Study 1836422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 7195247 — intervention group
Group type: COMPARATOR
Intervention: 1 x 20 mg/kg, 2 x 20 mg/kg, or 3 x 20 mg/kg (phase II A trial)
Number of subjects: 79
Study 7195247 — intervention group
Group type: COMPARATOR
Intervention: 1 x 30 mg/kg (n=53), 1 x 40 mg/kg (n=45), 2 x 20 mg/kg (n=53) (phase II B trial)
Number of subjects: 79
Study 7195247 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of 50 mg/kg (phase II A trial)
Number of subjects: 79
Study 7195247 — intervention group
Group type: COMPARATOR
Intervention: Three oral doses of 20 mg/kg given at 4-h intervals (phase II A trial)
Number of subjects: 79
Study 7195247 — intervention group
Group type: COMPARATOR
Intervention: 1 x 40 mg/kg (phase II B trial)
Number of subjects: 79
Study 31937169 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided excision
Number of subjects: 520
Study 31937169 — intervention group
Group type: COMPARATOR
Intervention: Wire-guided excision
Number of subjects: 520
Study 31296428 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 0
Study 31296428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28860511 — intervention group
Group type: EXPERIMENTAL
Intervention: InGaP (GaInP) photon counting X-ray photodiodes; 200 μm diameter; reverse bias above 5 V
Number of subjects: 4
Study 28860511 — intervention group
Group type: EXPERIMENTAL
Intervention: InGaP (GaInP) photon counting X-ray photodiodes; 400 μm diameter; reverse bias above 5 V
Number of subjects: 4
Study 28860511 — intervention group
Group type: EXPERIMENTAL
Intervention: System noise analysis
Number of subjects: 4
Study 25462656 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 21
Study 25462656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23625541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) positivity
Number of subjects: 109
Study 23625541 — intervention group
Group type: COMPARATOR
Intervention: Breslow thickness and ulceration status
Number of subjects: 109
Study 21247310 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy plus axillary dissection
Number of subjects: 3887
Study 21247310 — intervention group
Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy alone
Number of subjects: 3887
Study 19262951 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual fish consumption
Number of subjects: 867
Study 19262951 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for age, gender, and reported age at leaving full-time education
Number of subjects: 867
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: General Western medicine therapy and differential treatment of traditional Chinese medicine (TCM) based on stage classification
Number of subjects: 404
Study 17498487 — intervention group
Group type: COMPARATOR
Intervention: General Western medicine and placebo of traditional Chinese herbal medicine
Number of subjects: 404
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS (Glasgow coma scale)
Number of subjects: 404
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: NF (Nerve functional failure) scale
Number of subjects: 404
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: BI (Barther index) scale
Number of subjects: 404
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: QLI (Quality of life index) scale
Number of subjects: 404
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: FAQ (Functional activities questionnaire) scale
Number of subjects: 404
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL (Activity of daily living) scale
Number of subjects: 404
Study 17498487 — intervention group
Group type: EXPERIMENTAL
Intervention: ZH (syndromes of TCM) scale
Number of subjects: 404
Study 14999563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern-recognition methods (artificial neural networks, support vector machine, k-nearest neighbor) applied to MR imaging findings.
Number of subjects: 430
Study 14999563 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-propagation artificial neural network
Number of subjects: 430
Study 12774471 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (Amaril)
Number of subjects: 0
Study 12774471 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride (Amaril) combined with metformin, insulin, repaglynide, and nateglynide
Number of subjects: 0
Study 10198150 — intervention group
Group type: EXPERIMENTAL
Intervention: EMS
Number of subjects: 32
Study 10198150 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary (Vol)
Number of subjects: 32
Study 10198150 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote EMS (rEMS)
Number of subjects: 32
Study 10198150 — intervention group
Group type: COMPARATOR
Intervention: Control (Con)
Number of subjects: 32
Study 7775504 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine unit (moderate to high doses of morphine)
Number of subjects: 100
Study 7775504 — intervention group
Group type: COMPARATOR
Intervention: No-morphine unit (no morphine or morphine derivatives)
Number of subjects: 100
Study 2107240 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine, 1 mg/kg (mean dose, 69.6 ± 11.2 mg)
Number of subjects: 8
Study 2107240 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine, 0.12 mg/kg (mean dose, 8.4 ± 1.3 mg)
Number of subjects: 8
Study 6777801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.76 ml kg‐1 (orally)
Number of subjects: 0
Study 6777801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol at 0.15 ml kg‐1
Number of subjects: 0
Study 6777801 — intervention group
Group type: COMPARATOR
Intervention: Control (no ethanol)
Number of subjects: 0
Study 31034261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume eccentric training (1 set per exercise; 10 reps in total)
Number of subjects: 19
Study 31034261 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume eccentric training (4 sets; 40 reps)
Number of subjects: 19
Study 31034261 — intervention group
Group type: COMPARATOR
Intervention: Comparison between low-volume and high-volume training
Number of subjects: 19
Study 27841047 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 63
Study 27841047 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin
Number of subjects: 63
Study 26353009 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone monotherapy
Number of subjects: 195